MAP2K7 and melanoma: Importantly, we found that Mek inhibition in vivo determined a dramatic antitumor activity both in mutated- and wild type-BRAF tumors, suggesting that MEK inhibition, by different agents, might represent a powerful and safe strategy to counteract melanoma growth, thus improving patient outcome.